Table 2 Subgroup analysis of CR.

From: Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients

Characteristics

CR (n/%)

Non-CR (n/%)

P value

Age

  

0.229

<18 years

24 (88.9)

3 (11.1)

 

≥18 years

12 (100.0)

0 (0.0)

 

Gender

  

0.709

Female

16 (94.1)

1 (5.9)

 

Male

20 (90.9)

2 (9.1)

 

Number of previous chemotherapies

  

0.401

<4

15 (88.2)

2 (11.8)

 

≥4

21 (95.5)

1 (4.5)

 

Refractory disease

  

0.401

No

21 (95.5)

1 (4.5)

 

Yes

15 (88.2)

2 (11.8)

 

Relapsed disease

  

0.542

No

4 (100.0)

0 (0.0)

 

Yes

32 (91.4)

3 (8.6)

 

Bone marrow blasts

  

0.323

<5%

27 (90.0)

3 (10.0)

 

≥5%

9 (100.0)

0 (0.0)

 

Extramedullary disease

  

0.709

No

16 (94.1)

1 (5.9)

 

Yes

20 (90.9)

2 (9.1)

 

CNSL

  

0.920

No

25 (92.6)

2 (7.4)

 

Yes

11 (91.7)

1 (8.3)

 

BCR/ABL1

  

0.920

Negative

25 (92.6)

2 (7.4)

 

Positive

11 (91.7)

1 (8.3)

 

SH2B3 mutation

  

0.269

Negative

23 (95.8)

1 (4.2)

 

Positive

13 (86.7)

2 (13.3)

 

PAX5 mutation

  

0.202

Negative

25 (96.2)

1 (3.8)

 

Positive

11 (84.6)

2 (15.4)

 

WBC

  

0.079

<30 × 109/L

19 (100.0)

0 (0.0)

 

≥30 × 109/L

17 (85.0)

3 (15.0)

 

Lymphodepletion regimens

  

0.920

Flu + Cy

11 (91.7)

1 (8.3)

 

Non-Flu + Cy

25 (92.6)

2 (7.4)

 

CAR-T cells

  

0.248

Anti-CD19

24 (96.0)

1 (4.0)

 

Anti-CD19 + CD22

12 (85.7)

2 (14.3)

 
  1. Data were presented as count. Comparison was determined by χ2 test. P value <0.05 was considered significant.
  2. CR complete remission, CNSL central nervous system leukemia, WBC white blood cell, Flu fludarabine, Cy cyclophosphamide, CAR-T chimeric antigen receptor T cells.
Back to article page